Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06841770 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury
A Phase 1 study of Spinal Cord Injury and Spinal Cord Injury Cervical, sponsored by Lineage Cell Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT06841770 is a Phase 1 study of Spinal Cord Injury and Spinal Cord Injury Cervical that is actively recruiting participants, run by Lineage Cell Therapeutics. The registered enrollment target is 10 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06841770, a Phase 1 study of Spinal Cord Injury and Spinal Cord Injury Cervical, is actively recruiting participants, sponsored by Lineage Cell Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
The DOSED clinical study evaluates the safety and utility of a novel delivery device to deliver LCTOPC1, a cell therapy, to the spinal cord of patients with a spinal cord injury (SCI). LCTOPC1 is designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a goal to help improve the quality of life and restore or augment functional activity in persons suffering from a traumatic cervical or thoracic injuries.
Conditions Studied
Interventions
- BIOLOGICAL OPC1
Study Locations (2)
California
- Rancho Research Institue - Downey
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2037-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06841770
The ClinicalTrials.gov registry entry for NCT06841770 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (88% lower). The listed sponsor is Lineage Cell Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Spinal Cord Injury appearing as the primary indexed condition, and to 1 intervention - of which OPC1 is the first listed.
NCT06841770 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06841770 about?
NCT06841770 is a clinical study titled "A Study to Evaluate the Safety of a Delivery Device for Administering LCTOPC1 in Participants With Spinal Cord Injury". The DOSED clinical study evaluates the safety and utility of a novel delivery device to deliver LCTOPC1, a cell therapy, to the spinal cord of patients with a spinal cord injury (SCI). LCTOPC1 is designed to replace or support cells that are absent or dysfunctional due to traumatic injury, with a go...
What is the current status of trial NCT06841770?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-06-30. Estimated completion is 2037-06-30.
What conditions does trial NCT06841770 study?
This clinical trial studies the following conditions: Spinal Cord Injury, Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Chronic, Spinal Cord Injury, Acute.
What interventions are being tested in trial NCT06841770?
The interventions under investigation include: OPC1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06841770?
This trial is sponsored by Lineage Cell Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06841770 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury
RECRUITING · Phase 1
-
CE-STAND: Cervical Epidural STimulation After Neurologic Damage
RECRUITING · Phase 1
-
Platelet-Rich Plasma Therapy for Shoulder Pain in Persons With Spinal Cord Injury
COMPLETED · Phase 1
-
A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries
COMPLETED · Phase 1
-
Cortical Recording and Stimulating Array Brain-Machine Interface
RECRUITING · NA
-
Clinical Outcome Assessment for AT & BCI
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.